Article Topic
Prescription Drug Affordability Board Activity through October 18, 2024
Colorado’s board reviewed proposed changes to PDAB legislation based on stakeholder testimony and board review and learned about Medicare’s Maximum Fair Price (MFP) determination. Over two meetings, Oregon’s board reviewed a draft constituent group engagement report and a UPL model that analyzed potential 2023 savings based upon MFP provided by their consultants and aggregate data collected from PBMs. The board also discussed ; policy recommendations from staff and a UPL draft report required by Senate Bill 192.
[...]October 28, 2024: DOJ hands down indictments and patients harmed by formulary change
Chinese companies and individuals indicted by the Department of Justice and a study examines how patients were harmed by the sudden removal of a medication from a drug formulary.
[...]Plea Agreement, USA v Jeremy Brown
United States District Court Western District of Vermont USA v Jeremy Brown Plea Agreement Filed September 13, 2024 Read the document.
[...]Information, USA v Jeremy Brown
United States District Court Western District of Vermont USA v Jeremy Brown Information Filed September 13, 2024 Read the document.
[...]A DSCSA-newbies guide to the recent FDA DSCSA announcement
The FDA recently announced that “connected trading partners” that have made progress in transmitting electronic data that identifies and follow medicines made for the U.S. drug supply will not be penalized if they are still working out challenges in the process. Are you wondering what that means? We can explain.
[...]FDA Alert: Pain Relief-Marketed Dietary Supplement Recalled For Containing Prescription Steroids, Muscle Relaxants, and OTC Pain Relievers
Consumers taking this product should immediately consult with their health care professional to safely discontinue use of this product. The risks of withdrawal from corticosteroids should be assessed by a healthcare professional. Only licensed health care professionals can evaluate patients for the risk, or confirm the existence, of adrenal suppression. Consumers that have product which is being recalled should return to place of purchase or discard.
[...]PSM Advocates for SHOP SAFE legislation at Anti-Counterfeiting Day on the Hill
Our Executive Director, Shabbir Safdar, along with PSM members, shared examples of pharmaceutical counterfeits and helped attendees understand why current systems for stopping counterfeit product sales do not work well.
[...]October 7, 2024: DEA warning – Dozens of fake online pharmacies sold millions of fake pills to customers in all 50 states
An indictment by the Department of Justice against 18 individuals who allegedly sold counterfeit pills via dozens of fake pharmacy websites to residents in all 50 states prompts warnings from two additional federal agencies.
[...]What it means that the shortage of weight loss drugs is almost over
Drug shortages attract patient risk in many forms. Since first seeing compounded semaglutide for sale on Etsy in early 2023, the Partnership for Safe Medicines has recognized the unique threats that counterfeit and substandard versions of FDA-approved diabetes and obesity injectable medicines pose to consumer safety. Because unprecedented demand has outweighed the FDA-approved supply, PSM…
[...]September 30, 2024: 27 individuals indicted in Puerto Rico over wholesale distribution of misbranded and diverted medicine
Twenty-seven people in Puerto Rico indicted in misbranded and diverted drug case, CBP seized counterfeit and misbranded drugs in two states, and fake arthritis and cancer medications seized in India.
[...]